Third-generation inhibitors targeting EGFR T790M mutation in advanced non-small cell lung cancer
Abstract The tyrosine kinase inhibitors (TKI) against epidermal growth factor receptor (EGFR) are widely used in patients with non-small cell lung cancer (NSCLC). However, EGFR T790M mutation leads to resistance to most clinically available EGFR TKIs. Third-generation EGFR TKIs against the T790M mut...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2016-04-01
|
| Series: | Journal of Hematology & Oncology |
| Online Access: | http://link.springer.com/article/10.1186/s13045-016-0268-z |